The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
Open accessAbstract
Neisseria meningitidis is a major cause of endemic cases and epidemics of meningitis and devastating septicemia. Although effective vaccines exist for several serogroups of pathogenic N. meningitidis, conventional vaccinology approaches have failed to provide a universal solution for serogroup B (MenB) which consequently remains an important burden of disease worldwide. The advent of whole-genome sequencing changed the approach to vaccine development, enabling the identification of potential vaccine candidates starting directly with the genomic information, with a process named reverse vaccinology. The application of reverse vaccinology to MenB allowed the identification of new protein antigens able to induce bactericidal antibodies. Three highly immunogenic antigens (fHbp, NadA and NHBA) were combined with outer membrane vesicles and formulated for human use in a multicomponent vaccine, named 4CMenB. This is the first MenB vaccine based on recombinant proteins able to elicit a robust bactericidal immune response in adults, adolescents and infants against a broad range of serogroup B isolates. This review describes the successful story of the development of the 4CMenB vaccine, with particular emphasis on the functional, immunological and structural characterization of the protein antigens included in the vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,399
Self-citationComplete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58
Tettelin, H., Saunders, N. J., Heidelberg, J., Jeffries, A. C., Nelson, K. E., Eisen, J. A., Ketchum, K. A., Hood, D. W., Peden, J. F., Dodson, R. J., et al. (2000) · Science · doi:10.1126/science.287.5459.1809 · Cited by 1,097
Self-citationHUMAN IMMUNITY TO THE MENINGOCOCCUS
Goldschneider, I., Gotschlich, E. C., & Artenstein, M. S. (1969) · The Journal of Experimental Medicine · doi:10.1084/jem.129.6.1327 · Cited by 995
The lipocalin protein family: structural and sequence overview
Flower, D. R., North, A. C. T., & Sansom, C. E. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00148-5 · Cited by 868
Infectious diseases associated with complement deficiencies
Figueroa, J. E., & Densen, P. (1991) · Clinical Microbiology Reviews · doi:10.1128/cmr.4.3.359 · Cited by 729
A universal vaccine for serogroup B meningococcus
Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A., Capecchi, B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603940103 · Cited by 727
Self-citationSierra, G. V. G., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P., Sotolongo, P. F., Casanueva, G. V., Rico, C. O., Rodriguez, C. R., & Terry, M. H. (1991) · PubMed · Cited by 512
Reverse vaccinology, a genome-based approach to vaccine development
Rappuoli, R. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00554-5 · Cited by 497
Self-citationMicrobial adherence to and invasion through proteoglycans
Rostand, K. S., & Esko, J. D. (1997) · Infection and Immunity · doi:10.1128/iai.65.1.1-8.1997 · Cited by 490
Holst, J., Martin, D., Arnold, R., Huergo, C. C., Oster, P., O’Hallahan, J., & Rosenqvist, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.071 · Cited by 405
Cited by
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O., & De Gregorio, E. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151960 · Cited by 435
Self-citationParikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31921-3 · Cited by 275
Wei, H., Mo, J., Tao, L., Russell, R. J., Tymiak, A. A., Chen, G., Iacob, R. E., & Engen, J. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.019 · Cited by 208
Heras, B., Totsika, M., Peters, K. M., Paxman, J. J., Gee, C. L., Jarrott, R. J., Perugini, M. A., Whitten, A. E., & Schembri, M. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311592111 · Cited by 141
Emerging experience with meningococcal serogroup B protein vaccines
Toneatto, D., Pizza, M., Masignani, V., & Rappuoli, R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1308828 · Cited by 67
Self-citation
Metadata
- Authors
- Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 30
- Pages
- B87-B97
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2059359501
- Cited by
- 404
- References
- 99
- FWCI
- 23.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens. https://app.cochat.ai/papers/10.1016/j.vaccine.2012.01.033
- The paper
- Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012). The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens. Vaccine. https://doi.org/10.1016/j.vaccine.2012.01.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.